Protagenic Therapeutics announces private placement of up to $5 million
PTIX•
PTIX•Protagenic Therapeutics announced a private placement with $1.5 million in upfront gross proceeds and up to $3.5 million more possible from milestone-linked warrants. Funds will support PT00114 development, including a planned Phase 1/2a generalized anxiety disorder trial.
The private placement includes $1.5 million in upfront gross proceeds. Full exercise of two series of milestone-linked warrants could generate up to $3.5 million in additional gross proceeds. Proceeds will fund PT00114 IND-enabling activities, a planned Phase 1/2a generalized anxiety disorder trial, working capital and general corporate purposes. The company targets an IND submission in late first-quarter 2027 and first patient dosing in the second quarter, subject to FDA review; topline safety data are expected in the second half of 2027 and exploratory efficacy data in the first half of 2028.